Safety and tolerability of short‐term infusions of intravenous lacosamide in pediatric patients with epilepsy: An open‐label, phase 2/3 trial
Open Access
- 18 January 2023
- journal article
- research article
- Published by Wiley in Epilepsia Open
- Vol. 8 (1) , 146-153
Abstract
Objective: The objective of this study is to evaluate the safety and tolerability of intravenous (IV) lacosamide infusion in patients aged ≥1 month to <17 years with epilepsy.Methods: This Phase 2/3 open‐label trial (EP0060; NCT02710890) enrolled patients in two age cohorts (cohort 1: ≥8 to <17 years; cohort 2: ≥1 month to <8 years). Eligible patients were receiving oral lacosamide as adjunctive treatment or monotherapy (in an open‐label long‐term trial or by prescription) or were not receiving lacosamide before enrolment. Patients initiated IV lacosamide (2‐12 mg/kg/day or 100‐600 mg/day; 15‐60 minutes infusion) as a replacement for oral lacosamide or as adjunctive treatment. The primary outcomes were treatment‐emergent adverse events (TEAEs) and discontinuations due to TEAEs.Results: In total, 103 patients were enrolled and completed the trial; 55 patients were included in cohort 1 (≥8 to <17 years), 48 in cohort 2 (≥1 month to <8 years). During the 4 weeks before screening, 74 (71.8%) patients had focal seizures, 12 (11.7%) had generalized seizures, and two (1.9%) had unclassified seizures. Most patients (74 [71.8%]) initiated lacosamide as adjunctive IV treatment. The mean overall duration of exposure to IV lacosamide was 1.18 days. Seventy‐nine (76.7%) patients had one IV lacosamide infusion, 20 (19.4%) had two, one (1.0%) had three, and three (2.9%) had 10 infusions. Overall, five (4.9%) patients had a total of seven TEAEs. The only TEAEs reported in two or more patients were increased blood triglycerides (two [1.9%]). No serious or severe TEAEs were reported, and no patients discontinued due to TEAEs. No TEAEs were considered drug‐related by the investigator. No consistent or clinically relevant treatment‐related changes from baseline were observed for hematology, clinical chemistry parameters, vital signs, or 12‐lead electrocardiograms.Significance: IV lacosamide was generally well tolerated in pediatric patients (≥1 month to <17 years) with epilepsy, and no new safety concerns were identified.Keywords
Funding Information
- UCB Pharma
This publication has 13 references indexed in Scilit:
- Modeling and simulation for the evaluation of dose adaptation rules of intravenous lacosamide in childrenEpilepsy Research, 2019
- Effectiveness and Adverse Effect of Intravenous Lacosamide in Nonconvulsive Status Epilepticus and Acute Repetitive Seizures in ChildrenNeurology Research International, 2018
- Efficacy of lacosamide in children and adolescents with drug-resistant epilepsy and refractory status epilepticus: A systematic reviewSeizure: European Journal of Epilepsy, 2018
- Safety of intravenous lacosamide in critically ill childrenSeizure: European Journal of Epilepsy, 2017
- Clinical experience of intravenous lacosamide in infants and young childrenEuropean Journal of Paediatric Neurology, 2016
- Current understanding of the mechanism of action of the antiepileptic drug lacosamideEpilepsy Research, 2015
- Bioequivalence of Intravenous and Oral Formulations of the Antiepileptic Drug LacosamidePharmacology, 2012
- Safety and tolerability of adjunctive lacosamide intravenous loading dose in lacosamide‐naive patients with partial‐onset seizuresEpilepsia, 2012
- Intravenous lacosamide as short‐term replacement for oral lacosamide in partial‐onset seizuresEpilepsia, 2010
- Intravenous lacosamide as replacement for oral lacosamide in patients with partial‐onset seizuresEpilepsia, 2007